NAVAL DAVER to Molecular Targeted Therapy
This is a "connection" page, showing publications NAVAL DAVER has written about Molecular Targeted Therapy.
Connection Strength
1.747
-
Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019 02; 33(2):299-312.
Score: 0.311
-
Checkpoint inhibitors and aspergillosis in AML: the double hit hypothesis. Lancet Oncol. 2017 12; 18(12):1571-1573.
Score: 0.287
-
'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies. Curr Opin Hematol. 2017 03; 24(2):115-124.
Score: 0.273
-
Molecular targeted therapy in acute myeloid leukemia. Hematology. 2012 Apr; 17 Suppl 1:S59-62.
Score: 0.194
-
MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020 11; 34(11):2858-2874.
Score: 0.086
-
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discov. 2020 04; 10(4):506-525.
Score: 0.084
-
From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia. Drugs. 2019 Jul; 79(11):1177-1186.
Score: 0.080
-
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 03; 93(3):401-407.
Score: 0.072
-
Immunotherapy based approaches in myelofibrosis. Expert Rev Hematol. 2017 10; 10(10):903-914.
Score: 0.070
-
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Adv Exp Med Biol. 2017; 995:73-95.
Score: 0.067
-
Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognition. Future Oncol. 2017 Jan; 13(2):117-120.
Score: 0.066
-
Acute myeloid leukemia: advancing clinical trials and promising therapeutics. Expert Rev Hematol. 2016 May; 9(5):433-45.
Score: 0.064
-
Current status and research directions in acute myeloid leukemia. Blood Cancer J. 2024 09 19; 14(1):163.
Score: 0.029
-
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021 05 20; 11(5):98.
Score: 0.023
-
Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021 02 22; 11(2):41.
Score: 0.022
-
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018 03; 93(3):371-374.
Score: 0.018